Publication date: Feb 01, 2025
The treatment of relapsing-remitting multiple sclerosis (RRMS) is changing. There are limited data about initial treatment of RRMS in Finland. Our objectives were to study the trends of initial disease-modifying treatments (DMTs) for patients with RRMS from 2013 to 2022, treatment delays, factors associated with DMT choice, DMT switch patterns, and the effect of the COVID-19 pandemic. This retrospective register study used secondary data from the Finnish MS register. The DMTs were classified into medium-efficacy DMTs (meDMTs; beta interferons, glatiramer acetate, fumarates, and teriflunomide) and high-efficacy DMTs (heDMTs; alemtuzumab, cladribine, daclizumab, natalizumab, ocrelizumab, ofatumumab, and rituximab). The inclusion criteria were fulfilled by 2479 individuals. From 2013 to 2022, the proportion of heDMTs as the initial therapy increased by 5. 3-fold from 6. 9% to 43. 7% (p
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Multiple Sclerosis |
| disease | MESH | relapsing-remitting multiple sclerosis |
| disease | MESH | treatment delays |
| drug | DRUGBANK | Dimethyltryptamine |
| disease | MESH | COVID-19 pandemic |
| drug | DRUGBANK | Teriflunomide |
| drug | DRUGBANK | Alemtuzumab |
| drug | DRUGBANK | Cladribine |
| drug | DRUGBANK | Daclizumab |
| drug | DRUGBANK | Natalizumab |
| drug | DRUGBANK | Ocrelizumab |
| drug | DRUGBANK | Ofatumumab |
| drug | DRUGBANK | Rituximab |
| pathway | REACTOME | Reproduction |
| disease | IDO | process |
| disease | MESH | secondary progressive multiple sclerosis |
| drug | DRUGBANK | Elm |
| disease | IDO | symptom |
| disease | IDO | history |
| disease | MESH | relapses |
| drug | DRUGBANK | Dimethyl fumarate |
| drug | DRUGBANK | Fingolimod |
| drug | DRUGBANK | Ponesimod |
| drug | DRUGBANK | Azathioprine |
| drug | DRUGBANK | Mitoxantrone |
| disease | MESH | double vision |
| drug | DRUGBANK | Isoxaflutole |
| disease | MESH | optic neuritis |
| disease | MESH | paresthesia |
| drug | DRUGBANK | Sodium lauryl sulfate |
| drug | DRUGBANK | Coenzyme M |